— Zoetis Inc. (NYSE: ZTS) reported its fourth-quarter 2019 adjusted earnings of $0.92 per share versus $0.88 expected.
— Revenues grew 7% to $1.7 billion versus $1.64 billion expected. On an operational basis, revenue, excluding the impact of foreign exchange, increased by 9%.
— The US segment revenue rose by 6% as growth in key dermatology portfolio across both the Apoquel and Cytopoint brands drove sales of companion animal products higher by 15%.
— International revenue grew 9% on higher sales across key dermatology portfolio and in certain parasiticides, including Simparica and the Revolution/Stronghold franchise, as well as growth across key markets in Western Europe and in China.
— For full-year 2020, the company expects operational growth of 7% to 9.5% in revenue and 8% to 11% in adjusted net income.
— For the full year 2020, the company expects revenue in the range of $6.65-6.8 billion, EPS of $3.53-3.65 and adjusted EPS of $3.90-4.00. The consensus estimates EPS of $4.01 on revenue of $6.7 billion.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Trxade (MEDS) is increasing the breadth of product offerings: CEO Suren Ajjarapu
Trxade Health Inc. (NASDAQ: MEDS) is an online pharmaceutical marketplace that provides a platform for independent pharmacies to operate more effectively. The company’s digital platform helps optimize drug procurement and
AMAT Stock: Is now the right time to invest in Applied Materials?
It is estimated that the size of the global chip manufacturing equipment market would nearly double from the current levels to about $142 billion in the next eight years. Applied
Here’s a look at Take-Two Interactive Software’s (TTWO) expectations for the coming year
Shares of Take-Two Interactive Software (NASDAQ: TTWO) were down over 2% on Friday. The stock has dropped 32% year-to-date and 35% over the past 12 months. Earlier this week, the
